Limited Submission Opportunity: Mary Kay Foundation Innovative/Translational Cancer Research Grant

This is a joint competition for VU and VUMC investigators. All investigators should follow these instructions. Applications are due Dec. 3, 2020.

Vanderbilt (VU and VUMC, collaboratively) has been invited to nominate one candidate for the Mary Kay Foundation Innovative/Translational Cancer Research Grant program for 2021. These awards provide $100,000 over two years to support innovative translational research for cancers affecting women, including, but not limited to, ovarian, uterine, breast and/or cervical cancer.

The Mary Kay Foundation seeks to fund innovative research that will provide a scientific link between laboratory research and the clinic. Ultimately, such research would lead to improvement in the diagnosis, prognosis, prevention or treatment of cancer.

You can find a list of the previous award recipients here. Review additional guidelines in the RFP.

Eligibility guidelines

  • Principal investigator must be a full-time assistant professor or higher (assistant, associate or full professor).
  • Staff scientists, postdoctoral trainees and instructors are NOT eligible.
  • Up to one co-P.I. is permitted.
  • Maximum $100,000 award includes direct and indirect costs over a two-year period. (Indirect rate may not exceed 15 percent.)
  • U.S. citizenship is not required.

Internal application process

  • Anyone interested in being considered as Vanderbilt’s nominee must submit the following to LSO@vanderbilt.edu by 5 p.m. on Dec. 3. Please combine your materials into a single PDF and reference the program name in the subject line of the email.
  • Brief research plan including summary budget (two-page max including budget; see suggested example in RFP);
  • Statement of support from department chair/center director;
  • NIH Biosketch.

The chosen nominee will submit a full proposal to the foundation by the deadline of Feb. 5, 2021. Direct all questions about the application process to LSO@vanderbilt.edu.